Literature DB >> 28129260

Long-term outcomes of thoracic endovascular aortic repair: A single institution's 11-year experience.

Megan Brenner1, William Teeter, Muhammed Hadud, Melanie Hoehn, James O'Connor, Deborah Stein, Thomas Scalea.   

Abstract

BACKGROUND: Thoracic endovascular aortic repair (TEVAR) has largely replaced traditional open aortic repair for anatomically suitable lesions, however, long-term outcomes are unknown.
METHODS: All patients who underwent TEVAR from December 2004 to October 2015 at a single tertiary care institution were included. Demographics, injury pattern, operative details, outcomes, and surveillance were reviewed. Follow-up ranged from 2 to 132 months and was obtained from clinic notes and imaging reports.
RESULTS: A total of 88 patients underwent TEVAR; all suffered from blunt mechanisms, 72.7% were men. Median age, Injury Severity Score, and Trauma and Injury Severity Score was 47 (19.7), 38 (13.5), 0. 8 (0.34). Injuries included 2% grade II, 90% grade III, and 8% grade IV. Overall mortality was 6.8%, TEVAR-related mortality was 0%. Overall in-hospital complication rate was 57%, whereas TEVAR-related complication rate was 9.1%: four typ 1a endoleaks, two typ 2, and two typ 3. Of the typ 1 endoleaks, all required reoperation, whereas all types 2 and 3 endoleaks resolved on subsequent imaging. The left subclavian artery (LSCA) was intentionally covered at index operation in 19 patients (21.6%), and 7 patients (8%) had partial LSCA coverage. The rate of postoperative left upper extremity ischemia was 0%. Left carotid-subclavian bypasses were performed prophylactically in two patients before LSCA coverage at index operation. Eighty-seven percent of endograft access was by performed by open femoral artery exposure and one via retroperitoneal conduit. Percutaneous TEVAR (pTEVAR) was performed more recently in 11.4% of patients with no complications. Heparin was administered intraoperatively in 23 patients with TBI, and 12 patients were not heparinized; no adverse events or outcomes resulted from its use or lack thereof. First, second, and third surveillance imagings occurred at mean intervals of 14 days, 4 months, and 1 year, respectively. Percent of patients followed at 1, 3, and 5 years from operation was 62.1%, 25%, 13.6%, respectively.
CONCLUSION: TEVAR continues to be a feasible treatment modality for blunt traumatic aortic injury with minimal and early device and procedure-specific complications. Follow-up continues to be a significant challenge, and protocols for surveillance imaging are needed. This is the first study to describe access specific outcomes of pTEVAR in trauma patients. Long-term outcomes of TEVAR are still largely unknown; however, these data suggest that it may be at least comparable to open repair. LEVEL OF EVIDENCE: Prognostic/epidemiologic study, level IV; therapeutic study, level V.

Entities:  

Mesh:

Year:  2017        PMID: 28129260     DOI: 10.1097/TA.0000000000001365

Source DB:  PubMed          Journal:  J Trauma Acute Care Surg        ISSN: 2163-0755            Impact factor:   3.313


  3 in total

1.  Efficacy and safety of TEVAR with debranching technique for blunt traumatic aortic injury in patients with severe multiple trauma.

Authors:  Kenichiro Uchida; Tetsuro Nishimura; Hiromasa Yamamoto; Yasumitsu Mizobata
Journal:  Eur J Trauma Emerg Surg       Date:  2019-04-03       Impact factor: 3.693

Review 2.  Resuscitative endovascular balloon occlusion of the aorta in civilian pre-hospital care: a systematic review of the literature.

Authors:  Yaset Caicedo; Linda M Gallego; Hugo Jc Clavijo; Natalia Padilla-Londoño; Cindy-Natalia Gallego; Isabella Caicedo-Holguín; Mónica Guzmán-Rodríguez; Juan J Meléndez-Lugo; Alberto F García; Alexander E Salcedo; Michael W Parra; Fernando Rodríguez-Holguín; Carlos A Ordoñez
Journal:  Eur J Med Res       Date:  2022-10-17       Impact factor: 4.981

3.  A case of blunt thoracic aortic injury requiring ECMO for acute malperfusion before TEVAR.

Authors:  Daiki Wada; Koichi Hayakawa; Shuji Kanayama; Shuhei Maruyama; Hiromu Iwamura; Noriyuki Miyama; Fukuki Saito; Yasushi Nakamori; Yasuyuki Kuwagata
Journal:  Scand J Trauma Resusc Emerg Med       Date:  2017-11-22       Impact factor: 2.953

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.